Teneobio Announces Poseida’s Exercise of Four Commercial License Options for UniDabs to Targets for Advanced CAR T-cell Therapies
NEWARK, Calif., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Teneobio, Inc., a clinical stage next generation, multi-specific antibody therapeutics company, announced...